BNP (brain natriuretic peptide) and its subunit NT-proBNP (N-terminal pro-B-type natriuretic peptide) are used to evaluate heart failure and myocardial dysfunction in patients using cancer therapies and they are effective predictors of short- and long-term major adverse events after ischemic heart disease [111,112]. Here, NPPB is linked to heart failure.